We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

SkinBioTherapeutics plc (SBTX) Ord GBP0.01

Sell:16.25p Buy:16.75p 0 Change: 0.40p (2.35%)
Market closed Prices as at close on 6 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:16.25p
Buy:16.75p
Change: 0.40p (2.35%)
Market closed Prices as at close on 6 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:16.25p
Buy:16.75p
Change: 0.40p (2.35%)
Market closed Prices as at close on 6 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

SkinBioTherapeutics plc is a United Kingdom-based life science company focused on skin health. The principal activity of the Company is that of research and development focused on harnessing the microbiome for human health. The Company’s segments include UK, US, and EU. The Company is targeting a number of skin healthcare sectors, which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. Its platform technology, SkinBiotix, applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. It targets five specific skin healthcare sectors, such as cosmetics skincare, food supplements for the treatment of skin conditions, medical skin care, infection control in both the home and the hospital environment, and pharmaceuticals for the prescribed treatment of skin conditions. Its first product, AxisBiotix-Ps, is a food supplement to address the symptoms of mild to moderate psoriasis.

Contact details

Address:
The Core, Newcastle Helix
NEWCASTLE UPON TYNE
NE4 5TF
United Kingdom
Telephone:
+44 (0191) 4957325
Website:
https://www.skinbiotherapeutics.com/

Important dates

Future events
AGM 27 December 2024 27/12/24
Past events
Final results 04 December 2024 04/12/24
Trading Announcement 29 July 2024 29/07/24
Interim results 22 March 2024 22/03/24
Trading Announcement 06 February 2024 06/02/24
AGM 29 December 2023 29/12/23

General stock information

EPIC:
SBTX
ISIN:
GB00BF33H870
Market cap:
£37.92 million
Shares in issue:
228.44 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Stuart Ashman
    Chief Executive Officer, Executive Director
  • Manprit Randhawa
    Chief Financial Officer, Executive Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.